AUS
NZ
UK
CA
USA
IND
_07_03_2026_03_50_21_133108.jpg)
Nyrada Inc. (ASX:NYR), a clinical-stage biotech firm specialising in TRPC ion channel inhibitors, has initiated dosing of the first patient in its Phase IIa PROTECT-MI trial assessing Xolatryp® for minimizing cardiac tissue damage in heart attack patients. Concurrently, the company reported encouraging preclinical data highlighting anti-tumour efficacy and cardioprotective potential, while maintaining a strong cash reserve of AU$8.39 million and securing US patent protection for its lead compound.
Key Points
- Nyrada Inc. (ASX:NYR) focuses on developing Transient Receptor Potential Canonical (TRPC) ion channel inhibitors targeting diverse medical conditions.
- First patient dosed in Phase IIa PROTECT-MI trial evaluating Xolatryp® safety and effectiveness in reducing heart tissue injury in STEMI patients undergoing percutaneous coronary intervention.
- Recruitment sites activated at Nepean Hospital (NSW) and Sir Charles Gairdner Hospital (WA); five additional Australian sites progressing approvals; expansion into New Zealand sites underway; trial completion expected by 2027 with top-line data anticipated within three months post final dosing.
- Preclinical studies reveal Xolatryp’s anti-tumour activity in liver cancer models and cardioprotective effects against doxorubicin-induced cardiac damage; US FDA pre-IND meeting requested with IND submission planned by late 2026.
- Cash balance of AU$8.39 million as of 30 June 2026; AU$2.46 million R&D tax rebate received during the quarter; US Patent Office issued Notice of Allowance for Xolatryp’s chemical structure.
- Investors should track Phase IIa trial recruitment progress across Australia and New Zealand and monitor timing of FDA regulatory submissions.
Nyrada’s Targeted TRPC Ion Channel Inhibition Strategy for Cardioprotection
Nyrada Inc., incorporated in Delaware and headquartered in Sydney, is a clinical-stage biotechnology company dedicated to developing small-molecule therapies that inhibit Transient Receptor Potential Canonical (TRPC) ion channels. The company’s approach focuses on modulating excessive cellular calcium influx, a key factor in various diseases including cardiac injury, neuroprotection, and oncology. This targeted focus distinguishes Nyrada from broader drug discovery approaches prevalent in biotech.
The lead candidate, Xolatryp®, has completed a Phase I trial demonstrating safety, tolerability, and pharmacokinetics in healthy volunteers, paving the way for Phase IIa clinical evaluation based on regulatory confidence and mechanistic rationale.
Launch of PROTECT-MI Phase IIa Trial and Multi-Centre Recruitment
The dosing of the first patient in the Phase IIa PROTECT-MI trial marks a pivotal step in Nyrada’s clinical development. This study evaluates Xolatryp® for safety and preliminary efficacy in reducing reperfusion injury in patients with ST-Elevation Myocardial Infarction (STEMI) undergoing percutaneous coronary intervention (PCI). The trial targets a high-risk population susceptible to cardiac tissue damage during reperfusion, where Xolatryp®’s mechanism may offer therapeutic benefit.
Recruitment sites are active at Nepean Hospital (New South Wales) and Sir Charles Gairdner Hospital (Western Australia), with governance approvals advancing for five additional Australian sites. Discussions are ongoing with other sites in Australia and New Zealand. The company maintains flexibility to add sites based on recruitment performance and regulatory clearance. The trial is on schedule for completion in 2027, with final patient dosing expected mid-year.
Anticipated Timeline for PROTECT-MI Top-Line Data
Top-line results are expected approximately three months following the last patient’s 30-day post-dosing follow-up, projecting data availability in late 2027 or early 2028, assuming recruitment and follow-up timelines are met. The 30-day follow-up aligns with standard cardiac safety protocols, enabling comprehensive safety and efficacy assessments.
Preclinical Evidence of Anti-Tumour and Cardioprotective Effects
Nyrada announced preclinical findings demonstrating Xolatryp®’s anti-tumour efficacy in liver cancer models, both as monotherapy and combined with doxorubicin chemotherapy. The combination therapy showed the most significant tumour volume reduction and was well tolerated, indicating potential as an adjunct to enhance chemotherapy effectiveness.
These findings expand Xolatryp®’s potential clinical applications beyond cardiology, consistent with TRPC channel biology. However, clinical validation is required to confirm these effects in humans.
Cardioprotection Pilot Study Against Doxorubicin-Induced Cardiotoxicity
A pilot study assessing Xolatryp®’s cardioprotective potential in patients receiving doxorubicin chemotherapy revealed promising preliminary data. Doxorubicin is known to cause cardiomyopathy and heart failure. Biomarker analysis showed lower mean cardiac troponin I levels in the Xolatryp® group compared to controls, suggesting reduced cardiac injury.
The pilot confirmed the feasibility and tolerability of subcutaneous dosing, informing dose selection for a larger cardiomyopathy study that commenced in late Q4 FY2026, with results expected by mid Q1 FY2027. These studies position Xolatryp® as a candidate cardioprotective agent addressing a significant unmet need in oncology.
US Patent Approval Secures Intellectual Property Protection
During the quarter, Nyrada received a Notice of Allowance from the US Patent Office for its lead compound, with grant expected imminently. The patent covers Xolatryp®’s chemical structure and analogues, providing 20 years of protection from the September 2024 filing date, extending exclusivity through 2044 in the US market.
This patent strengthens the company’s commercial position, enhancing value in licensing or partnership negotiations and protecting potential derivative compounds.
FDA Regulatory Strategy and IND Submission Plans
Nyrada is preparing an investigational new drug (IND) application for submission to the US FDA, having requested a pre-IND meeting. The IND submission is targeted before the end of 2026. This strategy aims to enable US-based Phase II trials, accelerating development and expanding patient access.
Financial Status and Cash Flow Overview
As of 30 June 2026, Nyrada held AU$8.39 million in cash, up from AU$6.74 million at 31 March 2026. Quarterly cash outflows were approximately AU$1.66 million, partially offset by AU$60,000 in interest income. This cash position supports ongoing clinical and regulatory activities, with runway duration dependent on future expenditures.
The company received AU$2.46 million in R&D tax incentives for FY2025 and AU$0.83 million from option exercises during the quarter, providing non-dilutive funding and capital inflows. Related party payments, including director fees and management salaries, totalled about AU$219,000 for the quarter.
R&D Tax Incentive and Capital Management
The AU$2.46 million R&D tax credit received is a vital non-dilutive funding source supporting clinical and preclinical research. Combined with AU$0.83 million from option exercises, these funds reduce reliance on equity raises and debt financing, reflecting investor confidence.
Broad Therapeutic Potential and Pipeline Expansion
Beyond cardiology and oncology, Nyrada’s preclinical research explores Xolatryp®’s application in neuroprotection for stroke and traumatic brain injury models. This diversified portfolio supports a platform approach targeting multiple diseases linked to calcium-mediated cellular injury. Clinical validation remains essential before expanding indications beyond the Phase IIa PROTECT-MI cardiac trial.
Clinical Development Risks and Trial Execution Challenges
Nyrada faces typical clinical-stage biotech risks including patient recruitment delays, trial outcome uncertainties, and regulatory challenges. The company’s multi-site recruitment strategy aims to mitigate enrollment risks, but slower recruitment could postpone trial completion beyond mid-2027. Additionally, Phase IIa results may not confirm safety or efficacy, potentially requiring trial modifications or termination. FDA regulatory timelines may also impact IND submission and subsequent US development milestones.
